

1 **Steroid Hormone Biosynthesis and Dietary Related Metabolites** 2 **Associated with Excessive Daytime Sleepiness**

3
4 Tariq Faquih^{1,2,3,4}, Kaitlin Potts^{1,4}, Bing Yu⁵, Robert Kaplan⁶, Carmen R Isasi⁶, Qibin Qi⁵, Kent
5 D. Taylor⁷, Peter Y. Liu⁷, Russell P. Tracy⁸, Craig Johnson⁹, Stephen S. Rich¹⁰, Clary B. Clish¹¹,
6 Robert E. Gerzsten^{2,3}, Jerome I. Rotter⁷, Susan Redline^{1,4}, Tamar Sofer^{1,3,4,12*}, Heming
7 Wang^{1,2,4*}

- 8
9 1. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA.
10 2. Broad Institute, Cambridge, MA, USA
11 3. CardioVascular Institute (CVI), Beth Israel Deaconess Medical Center, Boston, MA, USA
12 4. Division of Sleep Medicine, Harvard University Medical School, Boston, MA, USA.
13 5. Department of Epidemiology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
14 6. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
15 7. Department of Paediatrics, Institute for Translational Genomics and Population Sciences, The Lundquist
16 Institute for Biomedical Innovation, Harbor-UCLA Medical Centre, Torrance, CA, USA
17 8. Department of Biochemistry, University of Vermont, Burlington, VT, USA
18 9. Department of Biostatistics, University of Washington, Seattle, USA
19 10. Centre for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
20 11. Metabolite Profiling Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA
21 12. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

22
23 *Equal contribution
24

25 **Summary**

26 **Background**

27 Excessive daytime sleepiness (EDS) is a complex sleep problem that affects approximately 33%
28 of the United States population. Although EDS usually occurs in conjunction with insufficient
29 sleep, and other sleep and circadian disorders, recent studies have shown unique genetic markers
30 and metabolic pathways underlying EDS. Here, we aimed to further elucidate the biological profile
31 of EDS using large scale single- and pathway-level metabolomics analyses.

33 **Methods**

34 Metabolomics data were available for 877 metabolites in 6,071 individuals from the Hispanic
35 Community Health Study/Study of Latinos (HCHS/SOL) and EDS was assessed using the

36 Epworth Sleepiness Scale (ESS) questionnaire. We performed linear regression for each
37 metabolite on continuous ESS, adjusting for demographic, lifestyle, and physiological
38 confounders, and in sex specific groups. Subsequently, gaussian graphical modelling was
39 performed coupled with pathway and enrichment analyses to generate a holistic interactive
40 network of the metabolomic profile of EDS associations.

41

42 **Findings**

43 We identified seven metabolites belonging to steroids, sphingomyelin, and long chain fatty acids
44 sub-pathways in the primary model associated with EDS, and an additional three metabolites in
45 the male-specific analysis. The identified metabolites particularly played a role in steroid hormone
46 biosynthesis.

47

48 **Interpretation**

49 Our findings indicate that an EDS metabolomic profile is characterized by endogenous and dietary
50 metabolites within the steroid hormone biosynthesis pathway, with some pathways that differ by
51 sex. Our findings identify potential pathways to target for addressing the causes or consequences
52 of EDS and related sleep disorders.

53

54 **Funding**

55 Details regarding funding supporting this work and all studies involved are provided in the
56 acknowledgments section.

57 **Keywords:** metabolomics, excessive daytime sleepiness, sleep, pregnenolone, cortisol

58 **Research in context**

59 **Evidence before this study**

60 There is a growing recognition of the paramount importance of sleep on health and cardiometabolic
61 disease. Excessive daytime sleepiness (EDS), one of the key common sleep treatment targets, has
62 been linked to increased risk of mortality, hypertension, cardiovascular disease, car accidents as
63 well as decrease in life quality, and productivity. Despite its impact on health, much remains
64 unknown about the biological mechanisms of EDS and if those mechanisms are independent from
65 other sleep disorders. Recent genetic evidence that shows that EDS is associated with specific
66 genetic biomarkers supports the need to further study the underlying biology of EDS.

67

68 **Added value of this study**

69 Here, we used measurements of metabolites, the products and by-products of metabolism to
70 identify the metabolomic profile of EDS. Metabolites are produced by the biological reactions
71 within the body via proteins—themselves products of genes—and by the breakdown of external
72 sources such as nutritional intake and breathing air pollutants. Therefore, metabolomics enables
73 study of the effects of nutrition, environmental exposures, and genetics. In this study we aimed to
74 identify the metabolites that were associated with excessive daytime sleepiness. Additionally, we
75 mapped these metabolites into a publicly available online biological network of human metabolism
76 pathways to obtain an understanding of our findings on a larger scale.

77

78 **Implications of all the available evidence**

79 Identifying the metabolites and pathways related to daytime sleepiness provides insights into the
80 biological mechanisms of EDS and suggests future research opportunities to identify targets for

81 prevention, prediction, and treatments for EDS and potentially other sleep disorders coupled with
82 sleepiness. In this study we found 7 such metabolites—some endogenously synthesised and some
83 obtained from dietary sources—associated with EDS. The network analysis implicated the steroid
84 hormone biosynthesis pathway as a shared pathway underlying those metabolites, and identified
85 linkages to key metabolites related to sleep: melatonin and cortisol metabolism.

86 **Introduction**

87 Excessive daytime sleepiness (EDS) is a prevalent symptom that affects up to 33% of the
88 population of the United States (1,2). The aetiology of EDS is heterogeneous and multi-factorial
89 (1–5), reflecting variable contributions of insufficient sleep, some occurring secondary to sleep
90 disorders such as sleep apnoea and circadian rhythm disorders, and others reflecting abnormalities
91 of sleep-wake control systems such as narcolepsy and idiopathic hypersomnia (3,6). EDS
92 frequently co-occurs with (and is often associated with increased incidence of) multiple clinical
93 outcomes, cardiometabolic disorders such as obesity, type 2 diabetes (1), hypertension (5,7), and
94 cardiovascular disease (2,4), impaired cognition (1,3), depression, psychiatric disorders (1–3),
95 mortality (1–3), and reduced life quality (1–3). Notably, patients with sleep apnoea with concurrent
96 EDS have been reported to have higher risk of cardiovascular disease outcomes than patients with
97 sleep apnoea without EDS (4). EDS also has strong implications for public health given its
98 contributions to work-related accidents (6), car crashes (8), and loss of productivity (2,6,9).
99 Despite the health and social and economic impact of EDS, its aetiology and biological
100 mechanisms are incompletely understood (2–5).

101

102 There are several challenges in evaluating the biological underpinnings of EDS. For one, although
103 EDS is strongly linked to sleep disorders, patients may exhibit EDS even after the appropriate

104 treatment of their respective sleep disorder (4). This indicates a potentially unique aetiology for
105 EDS outside of those that overlap with other sleep disorders (4). Another challenge is the large
106 inter-individual differences in EDS with overtly similar sleep disorders (3). Moreover, there are
107 differences in prevalence of EDS across population groups and socio-economic strata that are
108 poorly understood (9–11).

109

110 Our research approach for addressing EDS was guided by the following: First, there are genetic
111 factors associated with EDS as shown by a recent study in the UK Biobank which identified 42
112 EDS related loci (3). This finding supports previous research that hypothesized that EDS is driven
113 by biological and metabolic influences (3,6,9). Second, EDS and sleep traits are associated with
114 cardiometabolic outcomes (4). Since cardiometabolic disorders are characterized by metabolic
115 alterations, EDS may also be linked with metabolic alterations. The causal effects of these
116 associations can either be directional or bi-directional and can involve shared risk factors, such as
117 obesity (6). Accordingly, using metabolomics to quantify the association of a large number of
118 diverse metabolites with EDS—in turn capturing the effects of genetic, metabolomic, nutritional,
119 and environmental influences on an individual’s metabolic profile—holds considerable potential
120 for revealing etiological insights and advancing our understanding of EDS in multi-ethnic
121 populations. Consequently, this can provide potential biological targets for intervention in order
122 to alleviate EDS and reduce cardiometabolic risks. To our knowledge, there are a limited number
123 of metabolomics studies on EDS and all with very small sample sizes (12).

124

125 In this study we aimed to elucidate the underlying metabolomic profile of EDS using untargeted
126 metabolomic measurements in two large well-characterized cohorts: the Hispanic Community

127 Health Study/Study of Latinos (HCHS/SOL) followed by replication analysis in the Multi-Ethnic
128 Study of Atherosclerosis (MESA). In addition, we aimed to examine the links between previously
129 identified genetic loci and metabolites implicated with EDS in order to identify the directionality
130 of the potentially causal associations between EDS and metabolite measurements.

131 **Methods**

132 *Study Designs*

133 The HCHS/SOL is a community based prospective cohort study of 16,415 self-identified
134 Hispanic/Latino individuals recruited from randomly selected households from geographic areas
135 around four field centres across the United States (Chicago IL, Miami FL, Bronx NY, and San
136 Diego CA). Baseline examination took place between 2008 to 2011. Full details regarding the
137 sampling and study design were described previously (13,14). The baseline clinical examination
138 provided anthropometric, biological, behavioural, and sociodemographic assessments of study
139 participants. These included dietary intake questionnaires (two 24-hour recalls and food propensity
140 questionnaire(15)) to derive the Alternate Healthy Eating Index 2010 (AHEI-2010)(16), physical
141 activity assessment based on a modified version of the Global Physical Activity Questionnaire to
142 derive total physical activity in a week (MET-min/day)(17), the Center of Epidemiologic Studies
143 Depression Scale (18) to assess depression (CESD10), the State-Trait Anxiety Inventory (STAI10)
144 (19) to assess anxiety, self-report medication usage, smoking (never, former or current), alcohol
145 use (never, former or current), hypertension status (based on medication use, self-report, and if
146 systolic or diastolic blood pressure was greater than or equal to 140/90), and diabetes status as
147 defined by the American Diabetes Association (20). In addition, several sleep traits were collected
148 using self-report sleep questionnaires (Women's Health Initiative Insomnia Rating Scale
149 (WHIIRS)(21), and the Epworth Sleepiness Scale (ESS)(22). Participants also reported bedtime

150 and wake time during weekday and weekend days, from which weighted average sleep duration
151 was computed ($(5 \times \text{average weekday sleep duration} + 2 \times \text{average weekend sleep duration}) / 7$).
152 Sleep apnoea severity was assessed using respiratory event index (REI, 3% desaturation) scored
153 from in-home sleep apnoea test using the Apnea Risk Evaluation System (ARES Unicorder,
154 Advanced Brain Imaging, Carlsbad CA) (23). 7-day actigraphy derived sleep metrics were
155 collected and scored in the Sueño ancillary study (N= 2,252) between 2010 and 2013 using
156 Actiwatch Spectrum (Philips Respironics) (24). Using this data, sleep efficiency and sleep mid-
157 point were evaluated in this subsample.

158

159 Excessive daytime sleepiness was defined based on the ESS questionnaire (22). Briefly, ESS
160 includes 8 items regarding the likelihood of dozing off in different scenarios during the day on a
161 scale from 0 to 3. An overall ESS was derived from the individual item score and ranges from 0
162 to 24, with higher scores corresponding to higher sleepiness, wherein a score of 11 and above is
163 commonly use to define EDS (6,22). The ESS was available in 13,820 individuals in the
164 HCHS/SOL study. Details regarding the MESA study design and measurements, including
165 metabolomics methods, are provided in the supplementary materials.

166 *Metabolomic Measurements*

167 In HCHS/SOL, serum blood samples were collected at baseline (between June 2008–July 2011)
168 for all 16,415 individuals. Of these samples, 6,372 were sent to Metabolon for the quantification
169 of metabolomic measurements. Metabolomic quantification was performed in two batches, in 2017
170 and 2021 respectively, by Metabolon Inc. (Durham, NC) using their Discovery HD4 Ultra-High-
171 Performance Liquid Chromatography tandem mass spectrometry platform (25). Samples were
172 stored in -70°C freezers after collection until assayed (26). Overall, 4004 samples were measured

173 in the first batch and 2,368 were measured in the second batch. The samples of 152 individuals
174 were used for quantification in both batches. For these repeated measurements we only included
175 the measurements in batch 2. In addition, we excluded samples of two individuals that were
176 quantified twice within the first batch and 37 individual samples quantified twice within the second
177 batch. After these exclusions, 3,850 samples were available in the first batch and 2,330 samples
178 were available from the second batch. Therefore, after including only one sample per individual,
179 the total number of samples included was 6,071. After the metabolomics quantification was
180 performed, a total of 879 metabolites were quantified in the first batch and 1264 metabolites were
181 measured in the second batch. However, two metabolites were excluded in the first batch as they
182 were not detected in the included individuals with ESS data. Finally, we selected the overlapping
183 metabolites between the two batches—877 metabolites—for statistical analysis.

184 ***Metabolomics Data Processing in the HCHS/SOL study***

185 To mitigate the effect of outlier metabolite measurements we winsorized metabolite levels that
186 were 5 standard deviations from the mean.

187 Multiple imputation using chained equations was used to impute missing values in all metabolites
188 to produce 5 imputed datasets for batch 1 and batch 2 separately. The methodology applied was
189 described in detail in previously published work (27). The two batches were then merged into 5
190 imputed datasets. Finally, all metabolites were log transformed and centred and scaled to have a
191 mean of 0 and a standard deviation of 1.

192 ***Multivariable linear regression analysis***

193 We conducted a series of sequential covariate-adjusted models to assess the metabolite
194 associations with EDS. Summary of all model designs and a directed acyclic graph are provided

195 in Supplementary Table 1 and Supplementary Figure 1. Multivariable linear regression or logistic
196 regression was performed with continuous and dichotomized ESS (above vs below a score of 10)
197 for each metabolite separately. For the minimally adjusted model (Model 1) we adjusted for age,
198 BMI, gender, and 7-level classification of self-reported Hispanic background (Dominican, Central
199 American, Cuban, Mexican, Puerto Rican, South American, or “More than one/Other” heritage).
200 Sample weighting of the study design was accounted for as described (13). For the primary model
201 (Model 2) we additionally adjusted for self-reported alcohol, cigarette use and weekly physical
202 activity. A third model (Sleep Traits Model) was conducted to examine if the associations were
203 specific for EDS or reflected other measured sleep traits. This model adjusted for short and long
204 sleep duration (<7 and ≥9 hours) (28), insomnia (continuous), and sleep apnoea (continuous), in
205 conjunction and individually in addition to the previously listed primary confounders. All analyses
206 were repeated stratified by sex. To adjust for multiple testing, we used the method described by Li
207 and Ji et al (29) to calculate the independent number of metabolites. Accordingly, there we
208 calculated 390 independent metabolites and set the significance cutoff to $0.05/390 = 0.00013$.

209
210 Several additional sensitivity analyses were performed. First, we accounted for the effect of dietary
211 effects by adjusting for the AHEI-2010 score in the diet model. Second, we accounted for potential
212 confounding due to hypertension, statin usage, and diabetes in the comorbidities model. We
213 performed sensitivity analyses independently adjusting for anxiety (STAI10) and depression
214 (CESD10), as well time of blood draw in addition to the minimally adjusted model confounders.
215 An additional analysis was performed adjusting for the available sleep medications usage and shift
216 work status data in the Sueño ancillary.

217

218 In line with the prior EDS GWAS (3), a crude analysis was performed to examine the association
219 between the statistically significant metabolites with actigraphy derived sleep data in the Sueño
220 ancillary subset to understand their effects on subtypes of EDS (sleep insufficiency vs sleep
221 propensity). Specifically, metabolites linear associations with mean bedtime and wakeup times in
222 the weekday and weekend, mean daily sleep duration, and average daily sleep efficiency
223 (proportion of sleep duration in the total rest period) in individuals with at least 4 validated
224 actigraphy days (N= 1,852) were analysed without adjustment for other variables

225 *Network Analysis and Pathway analyses*

226 To provide context to the relationship between the metabolite associations with EDS across
227 biological pathways, we used a three-way approach to produce an interactive network. This
228 included (i) a method to capture statistically significant correlations between the measured
229 metabolites, , (ii) a pathway enrichment analysis and (iii) explication of a biologically driven
230 network between the metabolites and known reactions and pathways. First, gaussian graphical
231 modelling (GGM) using sparse inverse covariance estimation with the graphical lasso (30,31) was
232 used to calculate the correlations between the metabolites measured in the HCHS/SOL study. To
233 reduce the number of irrelevant metabolites in relation to EDS, we selected metabolites that were
234 associated with the outcome in each of the linear regression models (from either Model 1-2 for
235 either pooled and sex stratified analyses) and had a P value < 0.005. This step helps reduce the
236 number of irrelevant metabolites to the outcome and in turn unclutters the network and reduces
237 overfitting of metabolite connections. Results of the GGM analysis were then imported into
238 Cytoscape(32) to visualize the metabolites correlations. Second, the selected metabolites and a
239 selection of genes previously found to be associated with EDS (3) were supplied to the
240 MetaboAnalyst 6.0 online metabolomics analysis suite (33,34) to perform a pathway analysis

241 based on global testing (35) and “Metabolite Set Enrichment Analysis”. Specifically, we
242 performed pathway analysis using the metabolites only, followed by a joint pathway analysis using
243 both EDS associated genes (3) and metabolites. Pathway enrichment analysis was performed to
244 identify the most enriched pathways. Results of the joint pathway analysis and the pathway
245 enrichment analysis were then combined with the GMM network developed in the first step. Third,
246 additional annotations were added to the network within Cytoscape using the Metscape plug-in
247 (36). Metscape provided annotations for the metabolites and added nodes for relevant biological
248 reactions and genes involving pathways of the metabolites based on the data from the Kyoto
249 Encyclopaedia of Genes and Genomes (KEGG) and The Edinburgh Human Metabolic Network
250 (37) to our network. Moreover, biologically relevant intermediate metabolites involved in these
251 reactions and pathways, but not measured in our dataset, were added to the network and given a
252 unique labelling to distinguish them from the measured metabolites.
253 These steps resulted in a fully interactive webpage (Cytoscape JS) of networks that combined the
254 GGM approach as well as biologically driven pathway and enrichment analyses.

255 ***Mendelian randomization analysis***

256 Mendelian randomization (MR) analysis was performed using the TwoSampleMR R package (Version
257 0.6.0) (38). We used the metabolite quantitative trait locus (metabQTL) data from the Trans-Omics in
258 Precision Medicine (TOPMed) program Phase 1 TOPMed metabQTL produced as part of TOPMed
259 Metabolomics standard operating procedure work. This work included 16,359 individuals across 8
260 TOPMed studies using the Broad Institute and Beth Israel Metabolomics Platform or Metabolon platform.
261 Full details are provided in the Supplementary materials. Summary statistics for EDS were obtained from
262 the GWAS of the UK Biobank (N= 452,071) (3).
263 MR analysis was performed using the MR Egger, weighted median, inverse variance weighted, simple
264 mode, and weighted mode methods using statistically significant metabolites in all our analyses that were

265 also available in the TOPMed metabQTL as the exposure and EDS as the outcome. All analyses used
266 default minor allele frequency cutoff (MAF > 1%). Heterogenicity testing was performed using the
267 Cochran's Q statistic and directionality testing was performed using the MR Steiger directionality test (39).

268 *Ethics*

269 This work was approved by the Institutional Review Board of Brigham and Women's Hospital.
270 HCHS/SOL assessments were approved by the Institutional Review Boards of the participating
271 institutions. This study was approved by the institutional review boards of all MESA field
272 centres. All participants provided written informed consent in both studies.

273 *Role of funders*

274 The funders did not have a role in the study design, analysis, nor interpretation.
275

276 **Results**

277 *Population characteristics*

278 After exclusions of duplicate metabolomic measurements and individuals with missing ESS or
279 BMI, our study included 6,071 individuals of Hispanic/Latino background (Figure 1). The
280 characteristics of the study are summarized in Table 1. The distribution of individuals from each
281 field centre was similar and the majority of individuals self-identified as Mexicans (32.5%). The
282 mean age was 48.28 years and consisted of 60% women (N=3,635). Average BMI was
283 approximately 30 in both sexes. Overall mean of ESS was 5.79 and was slightly higher score in
284 men (5.98). Using the 10-point cutoff, 957 (15%) individuals were classified as having EDS (of
285 which 58% were women). Regarding other assessed sleep traits, 11% had moderate sleep apnoea
286 (Respiratory Event Index>15 events/hr; 59% of which were men), mean sleep duration was 7.91

287 hours, and the average insomnia score (WHIIRS) was 7.46. Finally, the reported average time of
288 blood sample collection was around 10am.

289 In total 877 metabolites were available for all individuals in this study. These metabolites included
290 320 lipids (36.4%), 175 amino acids (19.9%), 139 unannotated metabolites (15.8%), and 120
291 xenobiotics (13.6%)—which includes metabolites derived from medications, environmental
292 exposures, and nonessential dietary sources such as caffeine. The remaining metabolites belonged
293 to peptides, nucleotides, vitamins, carbohydrates, and partially characterized molecules.

294 ***Primary metabolite association analysis***

295 The minimally adjusted model (Model 1), adjusting for age, sex, BMI, and Hispanic background,
296 identified 7 metabolites ($P < 0.00013$) negatively associated with the ESS on the continuous scale
297 (Table 2; Supplementary Table S2, Supplementary Figure 2). Of these metabolites, 5 belonged to
298 lipids, specifically, long chain polyunsaturated fatty acids (PUFA), steroids (Pregnenolone and
299 Corticosteroids), and sphingomyelin. The remaining 2 metabolites (X-11470 and X-11444) were
300 unannotated, and their pathway was not available in the Metabolon database. All effect directions
301 were negative (i.e. higher ESS was associated with lower metabolite levels) and ranged between -
302 0.34 and -0.4. After further adjustment for smoking, alcohol use, and physical activity (MET-
303 min/day) in the primary model (Table 2; Supplementary Table S2), the effect estimates and their
304 direction remained consistent and only docosadienoate was no longer statistically significant ($p =$
305 1.41×10^{-04}). The diet model, adjusting for AHEI-2010 score (Table 2; Supplementary Table S2),
306 had minimal changes to the effect sizes and directions as well. However, the associations of
307 pregnenediol sulfate, tetrahydrocortisol glucuronide, and X-11444 were not statistically significant
308 in this model. Finally, after adjusting for comorbidities (Table 2; Supplementary Table S2) the
309 effect estimates remained consistent with the previous models, however, pregnenediol sulfate and

310 X-11444 were no longer significant. In addition to the associated metabolites, several
311 sphingomyelins and steroid related metabolites were borderline statistically significant (P value ~
312 0.0001) in all models (Supplementary Figure 3 and 4).

313 *Sleep traits analysis and sensitivity analyses*

314 After adjusting for sleep traits (insomnia, OSA, and sleep duration) in addition to the covariables
315 used in the primary model, diet, and comorbidities models respectively four of the metabolites
316 reported in the primary model remained statistically significant with slightly stronger effect sizes
317 in the same direction (negative direction) (Table 3 and Supplementary Tables S3, S6, and S7).
318 Effect sizes and directions remained consistent after adjusting for diet and comorbidities.
319 Individual adjustment of sleep traits (insomnia, OSA, long sleep, and short sleep) did not alter the
320 results. The only exception was the association of adrenate (22:4n6) with EDS which was only
321 significant after adjusting only for insomnia along with comorbidity confounders. For two
322 sensitivity analyses, neither the first sensitivity analysis (adjusting for the minimally adjusted
323 model in addition to blood draw timing, depression and stress scores) nor the second sensitivity
324 analysis (adjusting for shift work and sleep medications in the Sueño ancillary) altered the results
325 for the primary analyses (Supplementary Table S9 and S10).

326 *Sex stratified analyses*

327 The metabolomic profiles in the sex-stratified subpopulations exhibited distinct patterns in
328 comparison to the primary analyses. First, no significant associations were found in any female-
329 specific analyses (Supplementary Table S5). Second, the analysis for males identified 6
330 metabolites associated with EDS in the minimally adjusted analysis (Table 4; Supplementary
331 Table S4). Three of these metabolites were previously found to be associated with EDS in the

332 pooled analyses with both men and women: docosadienoate (22:2n6), X-11470, and
333 tetrahydrocortisol glucuronide. The other 3 metabolites were associated with EDS only in males:
334 two glycerophospholipid (GPC) phosphatidylcholines (1-stearoyl-2-arachidonoyl-GPC
335 (18:0/20:4) and 1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)) and tyramine O-sulfate. After
336 adjusting for variables in the primary model (model 2), X-11470 and tetrahydrocortisol
337 glucuronide were no longer significant. Adjusting for diet additionally excluded tyramine O-
338 sulfate from the significance threshold. Finally, compared to the original 6 metabolites identified
339 in the minimally adjusted analysis, in the comorbidity adjusted analysis tetrahydrocortisol
340 glucuronide and X-11470 were no longer significant and the remaining associations maintained the
341 same effect direction and similar effect sizes. However, an additional metabolite,
342 phenylacetylcarnitine, was significantly associated with EDS in males in the comorbidity adjusted
343 analysis only.

344 *Association with Actigraphy data*

345 Crude analysis was performed between the ten significant metabolites associated with EDS
346 identified in the prior analyses and the actigraphy measures in the Sueño subsample (summarized
347 in Table 5). Notably, dihomo-linoleate (20:2n6) and sphingomyelin (d18:2/16:0, d18:1/16:1),
348 which were associated with lower EDS, were associated with both longer sleep duration and higher
349 sleep efficiency, a pattern which reflects a higher sleep propensity subtype. Pregnenediol sulfate
350 was associated with shorter sleep duration and lower EDS. Finally, tetrahydrocortisol glucuronide
351 was associated with lower sleep efficiency and reduced EDS, which reflects a mixed association
352 of reduced sleepiness during daytime but reduced sleep efficiency during nighttime.

353 *Network and pathway enrichment*

354 Based on the correlations and metabolic network for the metabolites associated with EDS, we
355 found biological links with several pathways. Primarily, steroid hormone biosynthesis was at the
356 centre of biological pathways associated with EDS (Figure 2, Online supplementary materials,
357 <https://tofaquih.github.io/Metabolomics-Excessive-Daytime-Sleepiness/>). This was confirmed by
358 the pathway enrichment analysis. The enrichment was driven by pregnenediol sulfate,
359 tetrahydrocortisol glucuronide, and dihomo-linoleate (20:2n6) as well as the *CYP11A1*, *CYP11A2*,
360 and *CYP7B1* genes identified from the previous GWAS on EDS (3). These metabolites were also
361 linked to cortisol and cortisone metabolism. In turn, dihomo-linoleate (20:2n6) was correlated with
362 11 beta-hydroxyandrosteroone glucuronide (i.e. 6-hydroxymelatonin), linked to the metabolism of
363 melatonin and to the aforementioned genes. Tyramine O-sulfate also shared a biological reaction
364 and enzyme related to the CYP genes and melatonin pathways. Finally, sphingomyelin
365 (d18:2/16:0, d18:1/16:1) was as expected, correlated with other species of sphingomyelin. Those
366 sphingomyelins seem to be indirectly correlated with pregnenolone steroids as well.

367 *Replications in MESA*

368 Of the 11 statistically significant metabolites observed in HCHS using the Metabolon platform,
369 only four were available in the MESA samples assayed with the Broad platform: pregnenediol
370 sulfate (C₂₁H₃₄O₅S), pregnenolone sulfate, dihomo-linoleate (20:2n6), 1-stearoyl-2-
371 arachidonoyl-GPC (18:0/20:4), or sphingomyelin (d18:2/16:0, d18:1/16:1). None of these reached
372 statistical significance (P<0.05), although the direction of the associations was consistent with the
373 results from the HCHS/SOL study apart from dihomo-linoleate (Supplementary Table S8).

374 *Mendelian randomization Associations*

375 MR analysis was performed for eight metabolites that were reported in the analyses models, had a
376 an identifiable chemical name, and had available genetic summary statistics required for the MR
377 analysis: tetrahydrocortisol glucuronide, pregnenetriol sulfate, docosadienoate (22:2n6), dihomom-
378 linoleate (20:2n6), tyramine-O-sulfate, 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4), 1-palmitoyl-
379 2-arachidonoyl-GPC (16:0/20:4n6), and phenylacetylcarnitine. We identified statistically
380 significant associations ($p < 0.05$) for pregnenediol sulfate (inverse variance weighted (IVW) $\beta =$
381 -0.017 , $p = 0.044$), tetrahydrocortisol glucuronide (IVW $\beta = -0.013$, $p = 0.047$), and tyramine-O-
382 sulfate (IVW $\beta = 0.03$, $p = 0.004$), consistent with a potential causal (protective) association
383 between these metabolites and EDS. Full results are provided in Table 6. No heterogeneity or
384 horizontal pleiotropy were detected, and effect direction was confirmed for these results by the
385 Steiger directionality test.

386

387 **Discussion**

388 In this study we identified seven metabolites associated with EDS, and an additional four
389 associated specifically in the male stratified analysis. These metabolites were primarily driven by
390 steroid hormonal biosynthesis pathways as indicated in our pathway enrichment analysis and
391 network. First, we report two specific pregnenolone steroids(40), pregnenediol sulfate and
392 tetrahydrocortisol glucuronide, with higher levels associated with less sleepiness. These
393 associations were consistent with a causal association in our mendelian randomization analysis.
394 and maintained the same effect direction as our linear regression analyses. These metabolites are
395 involved in the pathways required for conversion to glucocorticoids, neurosteroids, androgens, and
396 cortisol (41,42). Furthermore, pregnenediol sulfate appears to have an immunosuppressive role in
397 certain infections(43) and tetrahydrocortisol glucuronide is a major metabolite of cortisol and a

398 marker of adrenocortical activity. Pregnenediol sulfate is also acutely regulated by the pituitary
399 hormone ACTH, which strongly implicates its regulation by the adrenal axis (40). Together, these
400 data suggest that the protective association between these adrenal steroids and EDS reflects an
401 immunosuppressive role of adrenocortical activation – a role that is consistent with known anti-
402 inflammatory effects of glucocorticoids. This interpretation is consistent with data that we and
403 others have generated showing that greater EDS in OSA is related to inflammation (44,45). In
404 addition, cortisol-testosterone balance is important for sleep and general health. Insufficient sleep
405 duration has been reported to disrupt the hormonal balance, leading to decreased testosterone and
406 increased cortisol levels (46). The role of the adrenal gland with EDS is further supported by
407 reported associations between androstenedione, which partakes in circadian regulation in the
408 adrenal gland, with ESS in men (47).

409
410 Notwithstanding the predominately adrenal origin of pregnenediol sulfate and tetrahydrocortisol
411 glucuronide, such steroids may not be of *exclusively* adrenal origin, so a role of ovarian activation
412 should also be considered particularly because steroids of gonadal origin exhibit differential
413 circadian and sleep regulation in a sex-specific manner (45,48). Notably, clinical trials (mostly
414 with male subjects) and observational studies have reported progesterone steroids—produced from
415 pregnenolones—and their derivatives partake in inducing sleep, act as a sedative, increase
416 somnolence, reduce sleep latency, reduce sleep apnoea and sleep breathing disorders, and increase
417 non rapid eye movement sleep (41,43). In women, progesterone concentrations are reduced post
418 menopause (41,42). This reduction, which occurs after menopause, is associated with longer sleep
419 latency and more difficulty maintaining sleep compared to premenopausal women (49–51); while
420 administration of progesterone in postmenopausal (52) women showed reduced wakefulness

421 during sleep based on a EEG clinical trial (53). In addition, regulation of progesterone levels (and
422 sex steroid hormones) has been linked to circadian rhythm (48) and menstrual phases in
423 premenopausal women (45). Although, progesterone levels have been hypothesized to be
424 protective of sleep apnoea and sleep disordered breathing in premenopausal women (54,55), the
425 prevalence of EDS has been reported in some studies to be higher in women than in men (56–58),
426 while other studies reported that the EDS was specifically higher in post/peri-menopausal women.

427
428 Another property of progesterone is its involvement with γ -Aminobutyric acid (GABA)
429 neurotransmitter. Progesterones (such as pregnenediol sulfate) and glucocorticoids (such as
430 tetrahydrocortisol) have been reported to exert an agnostic effect on the GABA_A receptor (59–61).
431 GABA_A receptors are major targets of sleep medications such as benzodiazepine used for
432 promoting sleep in patients with insomnia, anxiety, and other neurological disorders (62,63).
433 Indeed, the effect of progesterone on sleep quality in both men and women has been suggested to
434 be due to an interaction between progesterone and the GABA_A (similar to the action of
435 benzodiazepines) (41,53,59,64). Interestingly, after adjustment for diet quality, both metabolites
436 were no longer significantly associated with EDS. This is in line with the influence of diet and
437 cholesterol in the biosynthesis of these metabolites (65). Actigraphy analysis for pregnenediol
438 sulfate actigraphy metrics further indicates an association with of reduced sleepiness and shorter
439 sleep duration, indicating a sleepiness resilience despite shorter sleep duration.

440 We did not detect significant associations between progesterone steroids or any other metabolites
441 in analyses restricted to females. However, the effect direction was consistent with the primary
442 results. Thus, our findings from the linear regression and MR analyses for pregnenediol sulfate
443 and tetrahydrocortisol glucuronide are indicative of a larger role of glucocorticoid and adrenal

444 gland related hormones with EDS in men. Lack of significant findings for women, despite
445 progesterone steroids role as sex hormones particularly in women (41), could be due to the
446 complex regulation and menstrual cycle variation of progesterone levels in women and the
447 inclusion of women with different menopausal stages, which may have obscured potential
448 associations when examining the data stratified by sex. Future studies designed specifically to
449 examine women's health are needed to further understand sex-specific risk factors for EDS.

450

451 Second, we report two long chained fatty acids obtained primarily from dietary sources: omega-6
452 fatty acid dihomo-linoleate (20:2n6) (also known as dihomolinoleate or DGLA) and
453 docosadienoate (22:2n6) (i.e., docosadienoate). Accordingly, these metabolites are involved in
454 fatty acids metabolism and are upstream of docosahexaenoic acid (DHA) and other known fatty
455 acids (66). Interestingly docosadienoate was found to be associated with EDS when we adjusted
456 for diet and comorbidities. Although we did not find studies that found an association between
457 these two metabolites with EDS specifically, previous sleep research has examined the
458 associations of fatty acids intake in general with sleep quality and sleep disorders. Long chain fatty
459 acids are known to be involved in the production of melatonin and DHA supplementation has been
460 suggested to improve sleep quality (67,68). For example, a randomized control trial in children
461 between the ages of 7-9 (N=395) which concluded that higher levels of docosahexaenoic acid—
462 where associated with improved sleep in the children (69). Omega-6 fatty acids have also been
463 shown to be associated with sleep quality and slow wave sleep in obese individuals (66) and
464 consumption of omega-3 and omega-6 fatty acids rich foods was also associated with improved
465 sleep efficiency(70). Regarding the specific fatty acids reported in our study, dihomolinoleate was
466 associated with sleep midpoint (71) and both dihomolinoleate and docosadienoate were linked to,

467 and possibly regulated by, circadian rhythm (72). [The sources of these metabolites \(such as](#)
468 [vegetable oils, nuts, seeds and fatty fish\(73\)\) are abundant in Mediterranean-type diet, which in](#)
469 [turn has been associated with several positive sleep outcomes, including higher sleep quality\(74–](#)
470 [76\) and reduced daytime sleepiness\(77\).](#) Overall, our findings align with the literature regarding
471 the benefits of long chain fatty acids to improving sleep and, in this particular study, by reducing
472 sleepiness. Furthermore, our findings corroborate the role of long chain fatty acids for the
473 biosynthesis of melatonin, as indicated by their connection with pregnenolone steroids and
474 melatonin in the pathway enrichment network and analysis. Finally, actigraphy analysis implicates
475 there two metabolites with a reduced sleepiness and longer sleep duration.

476

477 Third, we have identified sphingomyelin (d18:2/16:0, d18:1/16:1) to be associated with reduced
478 EDS as well as four sphingomyelins—highly correlated with (d18:2/16:0, d18:1/16:1)—that were
479 borderline significant. Sphingomyelin and sphingolipids are integral in the biosynthesis and
480 regulation of steroid hormones and cortisol (78), particularly in adrenal cortex (78,79). In addition,
481 sphingolipid biosynthesis regulates the steroidogenic gene expression and activity (79). Thus, our
482 findings and pathway analysis is in line with biological pathway of sphingomyelin species in
483 relation to pregnenolone steroids and cortisol and their subsequent association with EDS.
484 Sphingomyelin has also been reported in previous metabolomic study on sleep disordered
485 breathing, hypertension, and type 2 diabetes (80).

486

487 Regarding the sex stratified analysis, an interesting association was that of tyramine O-sulfate with
488 EDS in males. In addition, mendelian randomization analysis for this metabolite further suggests
489 a potential causal association with EDS. Tyramine O-sulfate is a secondary metabolite of tyramine,

490 a monoamine that can occur endogenously or can be obtained from dietary sources (81,82) such
491 as fermented foods, wine, beer, coffee, cheese, among others (82). Tyramine levels are particularly
492 higher in overripe and spoiling food, thus high levels of tyramine are an indication of poor food
493 quality or poor food storage (82). As a monoamine, tyramine is related to, and partakes in the
494 biosynthesis of, monoamine neurotransmitters including serotonin, dopamine, histamine,
495 noradrenaline, adrenaline among others (81,83). Numerous research studies have reported the role
496 of monoamines on sleep. For instance, levels of these monoamine have been linked with sleep-
497 wake stages and circadian rhythms (83–86). Specifically, monoamines levels were higher during
498 sleep deprivation and remained at high levels during sleep recovery (86). In addition, monoamines
499 are generally lower during wake stages compared to sleep stages (86), and therefore consumption
500 of tyramine rich foods could lead to higher levels of monoamines, such as adrenaline can in turn
501 can negatively affect sleep (87). In relation to melatonin, some tyramine reactions involve the
502 monoamines oxidase enzymes (such as monoamine oxidase A and B), which in turn are related to
503 flavoprotein. Our network analysis also indicates that tyramine reactions shared the enzymatic
504 group (unspecific monooxygenase/flavoprotein monooxygenase) with melatonin, specifically 6-
505 hydroxymelatonin. Interestingly a study on mice examining the inhibitory and regulatory effects
506 of tyramine on monoamine oxidase reported an accumulation of 6-hydroxymelatonin, along with
507 tyramine, histamine, and taurine, in trace amine-associated receptor 1 (TAAR1) knock out mice
508 (88). As noted by that study, melatonin, histamine, and taurine are associated with sleep regulation,
509 circadian rhythms (88,89). Additionally, *TAAR1* has been associated with the regulation and
510 increase wakefulness in animal models (88,89) and a potential drug target for sleep disorders (90).
511 Another shared aspect between melatonin and tyramine are the CYP genes: *CYP1A1*, *CYP1A2*,
512 and *CYP7B1*. These three genes were included in our network analysis as they were previously

513 associated with EDS (3). These genes are also implicated with unspecific
514 monoxygenase/flavoprotein monoxygenase enzymes and metabolism, which involve
515 monoamines such as tyramine.

516 This body of evidence as well as our findings suggests a role of tyramine in sleepiness and possibly
517 sleep regulation. However, the exact biological pathway—whether via monoamine oxidase or
518 *TAARI* inhibition, or production of neurotransmitter monoamines, or by affecting melatonin
519 levels—remains unclear and beyond the scope of our study. Further studies to elucidate this
520 biological mechanism are required.

521
522 The two unannotated metabolites associated with EDS in the primary and stratified models, X-
523 11470 and X-11444, were directly found to be correlated with tyramine O-sulfate in our network
524 analysis. Based on a recent metabolome genome wide association study, both metabolites shared
525 the same locus and “metabotype” (i.e. a cluster of metabolites sharing at least one genetic signal)
526 on the *SRD5A2* gene along with 10 androgenic steroids related metabolites (91). This was further
527 supported by the direct feedback from the Metabolon structure analysis that predicted, based on
528 their chemical properties, that they were likely steroid glucuronides. Previous GWA studies
529 reported associations between *SRD5A2* locus has been associated with testosterone levels (92) and
530 hair loss/balding (92,93) in men. These findings and correlation of X-11470 and X-11444 with
531 tyramine O-sulfate could indicate the possible connection between androgenic steroids in men with
532 tyramine and sleepiness.

533
534 Finally, two GPCs (1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) and 1-palmitoyl-2-arachidonoyl-
535 GPC (16:0/20:4n6)) were associated with EDS in the men stratified analysis. GPCs are involved

536 in a wide range of biological functions, including biological involvement in pathways
537 encompassing dihomo-linoleate and docosadienoate (94,95). Similarly, they are derived from
538 dietary sources, such as fish, milk fat, and eggs, that have been associated with improved sleep
539 quality(70,96,97). Thus, their association with EDS is likely related to the fatty acids associations
540 we have identified and share similar dietary sources. In addition, GPCs specifically were reported
541 in previous sleep studies. GPCs found to be associated with blood pressure in obstructive sleep
542 apnoea in patients (94) and were increased in during sleep deprivation (98). 1-stearoyl-2-
543 arachidonoyl-GPC specifically was associated with sleep disordered breathing as well (80).

544

545 Our study had several strengths. We employed metabolomics analysis, examining a broad range
546 of metabolites across various biological pathways. This comprehensive approach, combined with
547 genomics and pathway analysis, yielded novel insights into EDS, particularly for the
548 Hispanic/Latino population. In addition, the scale and sample size of this study, is to our
549 knowledge, the largest metabolomic study on EDS to date (12). However, we were not able to
550 replicate the small set of available metabolites in the MESA study. Lack of replication in the
551 MESA study can be attributed to several factors. First, the sample available for the replication was
552 small which reduced the power of the analysis. Second, detected metabolites were between the
553 studies were inconsistent due to the different metabolomic measurement methodologies and
554 platforms used. For example, 1-stearoyl-2-arachidonoyl-GPC measurement was only available in
555 1,327 individuals while dihomo-linoleate was available in 1839 individuals. Third, the difference
556 in population characteristics, such as age—mean age of 48 in HCHS/SOL compared to 68 years
557 old in MESA) and ethnicity, can affect EDS and sleeping habits in general, as well as metabolomic
558 profiles (99). Finally, although the measurements in HCHS/SOL and MESA were performed using

559 platforms utilizing chromatography and mass spectrometry techniques, the process, overall
560 methodology, and final quantification of the metabolites are not identical. This is an important
561 factor that reduced our replication power as well.

562 ***Conclusions***

563 In conclusion, we have identified steroid hormone biosynthesis as the primary driver for the
564 metabolite associations with EDS via pregnenediol sulfate and tetrahydrocortisol metabolites and
565 potentially the GABA_A receptor. In addition, our findings suggest the role of dietary derived
566 metabolites, specifically fatty acids, sphingomyelin, GPC, and tyramine, on sleepiness. Tyramine
567 in particular could be of interest in future studies due to its association with the TAAR1 receptor,
568 a potential drug target for sleep disorders. These findings were supported by the previous GWAS
569 on EDS and pathway and enrichment analysis. Overall, these metabolites and pathway sheds light
570 on the metabolomic profile of EDS in the Hispanic/ Latino population, EDS profile differences in
571 males, and EDS in metabolomic profile in general.

572 **Contributors**

573 Tariq Faquih.: conceptualization, formal analysis, methodology, visualization, writing – original
574 draft.

575 K. P.: Writing – review & editing

576 Bing Yu: Writing – review & editing

577 Robert Kaplan: Project administration, Writing – review & editing

578 Carmen R Isasi: Project administration, Writing – review & editing

579 Qibin Qi: Writing – review & editing

580 Susan Redline: Supervision, Writing – review & editing

581 Tamar Sofer*: Funding acquisition, Supervision, Conceptualization, Writing – review & editing

582 Heming Wang*: Funding acquisition, Supervision, Conceptualization, Writing – review &
583 editing

584 **Declaration of Interests**

585 Dr. Redline discloses consulting relationships with Eli Lilly Inc, Jazz Pharma, and Apnimed Inc.
586 Additionally, Dr. Redline serves as an unpaid board member for the Alliance for Sleep Apnoea
587 Partners and has received loaned equipment for a multi-site study: oxygen concentrators from
588 Philips Respironics and polysomnography equipment from Nox Medical.

589 **Acknowledgments**

590 This work was supported by the National Institute of Health (NIH) grants R01HL153814 (to
591 H.W.), R01HL161012 (to T.S.). Support for metabolomics data was graciously provided by the
592 JLH Foundation (Houston, Texas). The Hispanic Community Health Study/Study of Latinos was
593 carried out as a collaborative study supported by contracts from the National Heart, Lung, and
594 Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of
595 Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern
596 University (N01-HC65236), and San Diego State University (N01-HC65237). The following
597 Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI:
598 National Center on Minority Health and Health Disparities, the National Institute of Deafness and
599 Other Communications Disorders, the National Institute of Dental and Craniofacial Research, the
600 National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of
601 Neurological Disorders and Stroke, and the Office of Dietary Supplements. The authors thank the
602 staff and participants of HCHS/SOL for their contributions.

603 The MESA projects are conducted and supported by the National Heart, Lung, and Blood Institute
604 in collaboration with MESA investigators. Support for MESA is provided by contracts
605 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160,
606 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006,

607 N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-
608 HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-
609 001079, and UL1-TR-001420, UL1TR001881, DK063491, and R01HL105756. A full list of
610 participating MESA investigators and institutes can be found at <http://www.mesa-nhlbi.org>. The
611 authors thank the other investigators, the staff, and the participants of the MESA study for their
612 contributions. Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was
613 supported by the National Heart, Lung and Blood Institute (NHLBI). Metabolomics for "NHLBI
614 TOPMed: "Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416) was performed at Broad
615 Institute and Beth Israel Metabolomics Platform (HHSN268201600034I). We gratefully
616 acknowledge the studies and participants who provided biological samples and data for TOPMed.
617 Phase 1 TOPMed metabQTL results were generated in a collaboration between the TOPMed
618 Metabolomics Working Group, the TOPMed Informatics Research Center, and the TOPMed
619 parent studies contributing metabolite data and distributed to TOPMed investigators.

620

621 **Data Sharing Statement**

622 HCHS/SOL study and MESA pseudonymized data are available via controlled-access application
623 to dbGaP (study accession phs000810 and phs003288.v1.p1) or via approved data use agreement
624 with the Data Coordinating Centre of the HCHS/SOL (University of North Carolina) and MESA
625 (University of Washington). For more details see <https://sites.csc.unc.edu/hchs> and
626 <https://internal.mesa-nhlbi.org/>. Individual WGS data for TOPMed and metabolomic data for
627 MESA can be obtained by application to dbGaP with accession number phs001416.v2.p1.

628

629 **References**

630

- 631 1. Gandhi KD, Mansukhani MP, Silber MH, Kolla BP. Excessive daytime sleepiness: A
632 clinical review. *Mayo Clin Proc.* 2021 May;96(5):1288–301.
- 633 2. Pérez-Carbonell L, Mignot E, Leschziner G, Dauvilliers Y. Understanding and
634 approaching excessive daytime sleepiness. *Lancet.* 2022 Sep 24;400(10357):1033–46.
- 635 3. Wang H, Lane JM, Jones SE, Dashti HS, Ollila HM, Wood AR, et al. Genome-wide
636 association analysis of self-reported daytime sleepiness identifies 42 loci that suggest
637 biological subtypes. *Nat Commun.* 2019 Aug 13;10(1):3503.
- 638 4. Bock J, Covassin N, Somers V. Excessive daytime sleepiness: an emerging marker of
639 cardiovascular risk. *Heart.* 2022 Oct 28;108(22):1761–6.
- 640 5. Covassin N, Somers VK. Somnolence. *Hypertension.* 2016 Nov;68(5):1100–2.
- 641 6. Slater G, Steier J. Excessive daytime sleepiness in sleep disorders. *J Thorac Dis.* 2012
642 Dec;4(6):608–16.
- 643 7. Goldstein IB, Ancoli-Israel S, Shapiro D. Relationship between daytime sleepiness and
644 blood pressure in healthy older adults. *Am J Hypertens.* 2004 Sep;17(9):787–92.
- 645 8. Connor J, Whitlock G, Norton R, Jackson R. The role of driver sleepiness in car crashes:
646 a systematic review of epidemiological studies. *Accident Analysis & Prevention.* 2001
647 Jan;33(1):31–41.
- 648 9. Barfield R, Wang H, Liu Y, Brody JA, Swenson B, Li R, et al. Epigenome-wide
649 association analysis of daytime sleepiness in the Multi-Ethnic Study of Atherosclerosis
650 reveals African-American-specific associations. *Sleep.* 2019 Aug 1;42(8).
- 651 10. Hayes AL, Spilsbury JC, Patel SR. The Epworth score in African American populations.
652 *J Clin Sleep Med.* 2009 Aug 15;5(4):344–8.
- 653 11. Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcántara C, et al. Racial/Ethnic
654 Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA).
655 *Sleep.* 2015 Jun 1;38(6):877–88.
- 656 12. Diallo I, Pak VM. Metabolomics, sleepiness, and sleep duration in sleep apnea. *Sleep*
657 *Breath.* 2020 Dec;24(4):1327–32.
- 658 13. Sorlie PD, Avilés-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML,
659 Giachello AL, et al. Design and implementation of the Hispanic Community Health
660 Study/Study of Latinos. *Ann Epidemiol.* 2010 Aug;20(8):629–41.

- 661 14. Lavange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, et al.
662 Sample design and cohort selection in the Hispanic Community Health Study/Study of
663 Latinos. *Ann Epidemiol*. 2010 Aug;20(8):642–9.
- 664 15. Siega-Riz AM, Sotres-Alvarez D, Ayala GX, Ginsberg M, Himes JH, Liu K, et al. Food-
665 group and nutrient-density intakes by Hispanic and Latino backgrounds in the Hispanic
666 Community Health Study/Study of Latinos. *Am J Clin Nutr*. 2014 Jun;99(6):1487–98.
- 667 16. Chiuve SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, et al. Alternative
668 dietary indices both strongly predict risk of chronic disease. *J Nutr*. 2012
669 Jun;142(6):1009–18.
- 670 17. Hispanic Community Health Study / Study of Latinos. HCHS/SOL Question by Question
671 Instructions Physical Activity Form (PAE/PAS), Version A. 2007 May 12 [cited 2024 Jul
672 1]; Available from:
673 [https://sites.csc.unc.edu/hchs/system/files/forms/UNLICOMMPHysicalActivityQxQ030](https://sites.csc.unc.edu/hchs/system/files/forms/UNLICOMMPHysicalActivityQxQ03062008.pdf)
674 [62008.pdf](https://sites.csc.unc.edu/hchs/system/files/forms/UNLICOMMPHysicalActivityQxQ03062008.pdf)
- 675 18. Radloff LS. The CES-D scale: A self-report depression scale for research in the general
676 population. *Appl Psychol Meas*. 1977 Jun 1;1(3):385–401.
- 677 19. Ferreira R, Murray J. Spielberger’s State-Trait Anxiety Inventory: Measuring anxiety
678 with and without an audience during performance on a stabilometer. *Percept Mot Skills*.
679 1983 Aug;57(1):15–8.
- 680 20. American Diabetes Association. Diagnosis and classification of diabetes mellitus.
681 *Diabetes Care*. 2010 Jan;33 Suppl 1(Suppl 1):S62-9.
- 682 21. Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ, et al.
683 Reliability and validity of the Women’s Health Initiative Insomnia Rating Scale. *Psychol*
684 *Assess*. 2003 Jun;15(2):137–48.
- 685 22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
686 scale. *Sleep*. 1991 Dec;14(6):540–5.
- 687 23. Redline S, Sotres-Alvarez D, Loredó J, Hall M, Patel SR, Ramos A, et al. Sleep-
688 disordered breathing in Hispanic/Latino individuals of diverse backgrounds. *The*
689 *Hispanic Community Health Study/Study of Latinos*. *Am J Respir Crit Care Med*. 2014
690 Feb 1;189(3):335–44.
- 691 24. Savin KL, Patel SR, Clark TL, Bravin JI, Roesch SC, Sotres-Alvarez D, et al.
692 Relationships of Sleep Duration, Midpoint, and Variability with Physical Activity in the
693 HCHS/SOL Sueño Ancillary Study. *Behav Sleep Med*. 2021;19(5):577–88.
- 694 25. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted
695 ultrahigh performance liquid chromatography/electrospray ionization tandem mass

- 696 spectrometry platform for the identification and relative quantification of the small-
697 molecule complement of biological systems. *Anal Chem.* 2009 Aug 15;81(16):6656–67.
- 698 26. Zhang Y, Ngo D, Yu B, Shah NA, Chen H, Ramos AR, et al. Development and
699 validation of a metabolite index for obstructive sleep apnea across race/ethnicities. *Sci*
700 *Rep.* 2022 Dec 16;12(1):21805.
- 701 27. Faquih T, van Smeden M, Luo J, le Cessie S, Kastenmüller G, Krumsiek J, et al. A
702 workflow for missing values imputation of untargeted metabolomics data. *Metabolites.*
703 2020 Nov 26;10(12).
- 704 28. Zhang Y, Elgart M, Granot-Hershkovitz E, Wang H, Tarraf W, Ramos AR, et al. Genetic
705 associations between sleep traits and cognitive ageing outcomes in the Hispanic
706 Community Health Study/Study of Latinos. *EBioMedicine.* 2023 Jan;87:104393.
- 707 29. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a
708 correlation matrix. *Heredity.* 2005 Sep;95(3):221–7.
- 709 30. Friedman J, Hastie T, Tibshirani R. Sparse inverse covariance estimation with the
710 graphical lasso. *Biostatistics.* 2008 Jul;9(3):432–41.
- 711 31. Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. qgraph : network
712 visualizations of relationships in psychometric data. *J Stat Softw.* 2012;48(4).
- 713 32. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a
714 software environment for integrated models of biomolecular interaction networks.
715 *Genome Res.* 2003 Nov;13(11):2498–504.
- 716 33. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for
717 metabolomic data analysis and interpretation. *Nucleic Acids Res.* 2009 Jul;37(Web
718 Server issue):W652-60.
- 719 34. Lu Y, Pang Z, Xia J. Comprehensive investigation of pathway enrichment methods for
720 functional interpretation of LC-MS global metabolomics data. *Brief Bioinformatics.* 2023
721 Jan 19;24(1).
- 722 35. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of
723 genes: testing association with a clinical outcome. *Bioinformatics.* 2004 Jan 1;20(1):93–9.
- 724 36. Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, et al.
725 Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and
726 gene expression data. *Bioinformatics.* 2012 Feb 1;28(3):373–80.
- 727 37. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, et al. The Edinburgh human
728 metabolic network reconstruction and its functional analysis. *Mol Syst Biol.* 2007 Sep
729 18;3:135.

- 730 38. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
731 platform supports systematic causal inference across the human phenome. *eLife*. 2018
732 May 30;7.
- 733 39. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
734 imprecisely measured traits using GWAS summary data. *PLoS Genet*. 2017 Nov
735 17;13(11):e1007081.
- 736 40. Rege J, Nanba AT, Auchus RJ, Ren J, Peng H-M, Rainey WE, et al. Adrenocorticotropin
737 acutely regulates pregnenolone sulfate production by the human adrenal in vivo and in
738 vitro. *J Clin Endocrinol Metab*. 2018 Jan 1;103(1):320–7.
- 739 41. Andersen ML, Bittencourt LRA, Antunes IB, Tufik S. Effects of progesterone on sleep: a
740 possible pharmacological treatment for sleep-breathing disorders? *Curr Med Chem*.
741 2006;13(29):3575–82.
- 742 42. Kolatorova L, Vitku J, Suchopar J, Hill M, Parizek A. Progesterone: A Steroid with Wide
743 Range of Effects in Physiology as Well as Human Medicine. *Int J Mol Sci*. 2022 Jul
744 20;23(14).
- 745 43. Abdrabou W, Dieng MM, Diawara A, Sermé SS, Almojil D, Sombié S, et al.
746 Metabolome modulation of the host adaptive immunity in human malaria. *Nat Metab*.
747 2021 Jul;3(7):1001–16.
- 748 44. Li Y, Vgontzas AN, Fernandez-Mendoza J, Kritikou I, Basta M, Pejovic S, et al.
749 Objective, but not subjective, sleepiness is associated with inflammation in sleep apnea.
750 *Sleep*. 2017 Feb 1;40(2).
- 751 45. Rahman SA, Grant LK, Gooley JJ, Rajaratnam SMW, Czeisler CA, Lockley SW.
752 Endogenous circadian regulation of female reproductive hormones. *J Clin Endocrinol*
753 *Metab*. 2019 Dec 1;104(12):6049–59.
- 754 46. Liu PY, Reddy RT. Sleep, testosterone and cortisol balance, and ageing men. *Rev Endocr*
755 *Metab Disord*. 2022 Dec;23(6):1323–39.
- 756 47. Kische H, Ewert R, Fietze I, Gross S, Wallaschofski H, Völzke H, et al. Sex Hormones
757 and Sleep in Men and Women From the General Population: A Cross-Sectional
758 Observational Study. *J Clin Endocrinol Metab*. 2016 Nov;101(11):3968–77.
- 759 48. Kelly MR, Yuen F, Satterfield BC, Auchus RJ, Gaddameedhi S, Van Dongen HPA, et al.
760 Endogenous Diurnal Patterns of Adrenal and Gonadal Hormones During a 24-Hour
761 Constant Routine After Simulated Shift Work. *J Endocr Soc*. 2022 Oct 26;6(12):bvac153.
- 762 49. Baker A, Simpson S, Dawson D. Sleep disruption and mood changes associated with
763 menopause. *J Psychosom Res*. 1997 Oct;43(4):359–69.

- 764 50. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal
765 dynamics in the perimenopause. *J Clin Endocrinol Metab.* 1996 Apr;81(4):1495–501.
- 766 51. Beverly Hery CM, Hale L, Naughton MJ. Contributions of the Women’s Health Initiative
767 to understanding associations between sleep duration, insomnia symptoms, and sleep-
768 disordered breathing across a range of health outcomes in postmenopausal women. *Sleep*
769 *Health.* 2020 Feb;6(1):48–59.
- 770 52. Shahar E, Redline S, Young T, Boland LL, Baldwin CM, Nieto FJ, et al. Hormone
771 replacement therapy and sleep-disordered breathing. *Am J Respir Crit Care Med.* 2003
772 May 1;167(9):1186–92.
- 773 53. Schüssler P, Kluge M, Yassouridis A, Dresler M, Held K, Zihl J, et al. Progesterone
774 reduces wakefulness in sleep EEG and has no effect on cognition in healthy
775 postmenopausal women. *Psychoneuroendocrinology.* 2008 Sep;33(8):1124–31.
- 776 54. Sigurðardóttir ES, Gislason T, Benediktsdóttir B, Hustad S, Dadvand P, Demoly P, et al.
777 Female sex hormones and symptoms of obstructive sleep apnea in European women of a
778 population-based cohort. *PLoS ONE.* 2022 Jun 22;17(6):e0269569.
- 779 55. Driver HS, McLean H, Kumar DV, Farr N, Day AG, Fitzpatrick MF. The influence of
780 the menstrual cycle on upper airway resistance and breathing during sleep. *Sleep.* 2005
781 Apr;28(4):449–56.
- 782 56. Lindberg E, Janson C, Gislason T, Björnsson E, Hetta J, Boman G. Sleep disturbances in
783 a young adult population: can gender differences be explained by differences in
784 psychological status? *Sleep.* 1997 Jun;20(6):381–7.
- 785 57. Rockwood K, Davis HS, Merry HR, MacKnight C, McDowell I. Sleep disturbances and
786 mortality: results from the Canadian Study of Health and Aging. *J Am Geriatr Soc.* 2001
787 May;49(5):639–41.
- 788 58. Theorell-Haglöw J, Lindberg E, Janson C. What are the important risk factors for
789 daytime sleepiness and fatigue in women? *Sleep.* 2006 Jun;29(6):751–7.
- 790 59. Wang M, He Y, Eisenman LN, Fields C, Zeng C-M, Mathews J, et al. 3beta -
791 hydroxypregnane steroids are pregnenolone sulfate-like GABA(A) receptor antagonists. *J*
792 *Neurosci.* 2002 May 1;22(9):3366–75.
- 793 60. Steiger A, Trachsel L, Guldner J, Hemmeter U, Rothe B, Rupperecht R, et al.
794 Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse
795 agonistic GABAA-receptor modulation. *Brain Res.* 1993 Jul 2;615(2):267–74.
- 796 61. Lancel M, Faulhaber J, Holsboer F, Rupperecht R. Progesterone induces changes in sleep
797 comparable to those of agonistic GABAA receptor modulators. *Am J Physiol.* 1996
798 Oct;271(4 Pt 1):E763-72.

- 799 62. Gottesmann C. GABA mechanisms and sleep. *Neuroscience*. 2002;111(2):231–9.
- 800 63. Nielsen S. Benzodiazepines. *Curr Top Behav Neurosci*. 2017;34:141–59.
- 801 64. Friess E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R. Progesterone-induced changes
802 in sleep in male subjects. *Am J Physiol*. 1997 May;272(5 Pt 1):E885-91.
- 803 65. Jacobs MN, Lewis DFV. Steroid hormone receptors and dietary ligands: a selected
804 review. *Proc Nutr Soc*. 2002 Feb;61(1):105–22.
- 805 66. Papandreou C. Polyunsaturated fatty acids in relation to sleep quality and depression in
806 obstructive sleep apnea hypopnea syndrome. *Omega-3 Fatty Acids in Brain and*
807 *Neurological Health*. Elsevier; 2014. p. 337–47.
- 808 67. Papandreou C, Camacho-Barcia L, García-Gavilán J, Hansen TT, Hjorth MF, Halford
809 JCG, et al. Circulating metabolites associated with objectively measured sleep duration
810 and sleep variability in overweight/obese participants: a metabolomics approach within
811 the SATIN study. *Sleep*. 2019 May 1;42(5).
- 812 68. Peuhkuri K, Sihvola N, Korpela R. Diet promotes sleep duration and quality. *Nutr Res*.
813 2012 May;32(5):309–19.
- 814 69. Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Fatty acids and
815 sleep in UK children: subjective and pilot objective sleep results from the DOLAB study-
816 -a randomized controlled trial. *J Sleep Res*. 2014 Aug;23(4):364–88.
- 817 70. Hansen AL, Dahl L, Olson G, Thornton D, Graff IE, Frøyland L, et al. Fish consumption,
818 sleep, daily functioning, and heart rate variability. *J Clin Sleep Med*. 2014 May
819 15;10(5):567–75.
- 820 71. Xiao Q, Derkach A, Moore SC, Zheng W, Shu X-O, Gu F, et al. Habitual Sleep and
821 human plasma metabolomics. *Metabolomics*. 2017 May;13(5).
- 822 72. Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA. The human circadian
823 metabolome. *Proc Natl Acad Sci USA*. 2012 Feb 14;109(7):2625–9.
- 824 73. Mustonen A-M, Nieminen P. Dihomo- γ -Linolenic Acid (20:3n-6)-Metabolism,
825 Derivatives, and Potential Significance in Chronic Inflammation. *Int J Mol Sci*. 2023 Jan
826 20;24(3).
- 827 74. Campanini MZ, Guallar-Castillón P, Rodríguez-Artalejo F, Lopez-Garcia E.
828 Mediterranean diet and changes in sleep duration and indicators of sleep quality in older
829 adults. *Sleep*. 2017 Mar 1;40(3).

- 830 75. Castro-Diehl C, Wood AC, Redline S, Reid M, Johnson DA, Maras JE, et al.
831 Mediterranean diet pattern and sleep duration and insomnia symptoms in the Multi-Ethnic
832 Study of Atherosclerosis. *Sleep*. 2018 Nov 1;41(11).
- 833 76. Godos J, Ferri R, Caraci F, Cosentino FII, Castellano S, Galvano F, et al. Adherence to
834 the Mediterranean Diet is Associated with Better Sleep Quality in Italian Adults.
835 *Nutrients*. 2019 Apr 28;11(5).
- 836 77. Ferranti R, Marventano S, Castellano S, Giogianni G, Nolfo F, Rametta S, et al. Sleep
837 quality and duration is related with diet and obesity in young adolescent living in Sicily,
838 Southern Italy. *Sleep Sci*. 2016 Apr 14;9(2):117–22.
- 839 78. Lucki NC, Sewer MB. The interplay between bioactive sphingolipids and steroid
840 hormones. *Steroids*. 2010 Jun;75(6):390–9.
- 841 79. Lucki NC, Sewer MB. Multiple roles for sphingolipids in steroid hormone biosynthesis.
842 *Subcell Biochem*. 2008;49:387–412.
- 843 80. Zhang Y, Yu B, Qi Q, Azarbarzin A, Chen H, Shah NA, et al. Metabolomic profiles of
844 sleep-disordered breathing are associated with hypertension and diabetes mellitus
845 development. *Nat Commun*. 2024 Feb 28;15(1):1845.
- 846 81. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. *Biochem*
847 *Biophys Res Commun*. 1998 Aug 28;249(3):838–43.
- 848 82. Burns C, Kidron A. *Biochemistry, Tyramine*. StatPearls. Treasure Island (FL): StatPearls
849 Publishing; 2024.
- 850 83. Scammell TE. Overview of sleep: the neurologic processes of the sleep-wake cycle. *J*
851 *Clin Psychiatry*. 2015 May;76(5):e13.
- 852 84. Monti J, Jantos H. The roles of dopamine and serotonin, and of their receptors, in
853 regulating sleep and waking. *Serotonin–dopamine interaction: experimental evidence and*
854 *therapeutic relevance*. Elsevier; 2008. p. 625–46.
- 855 85. Jouvet M. Sleep and serotonin: an unfinished story. *Neuropsychopharmacology*. 1999
856 Aug;21(2 Suppl):24S-27S.
- 857 86. Menon JML, Nolten C, Achterberg EJM, Joosten RNJMA, Dematteis M, Feenstra MGP,
858 et al. Brain Microdialysate Monoamines in Relation to Circadian Rhythms, Sleep, and
859 Sleep Deprivation - a Systematic Review, Network Meta-analysis, and New Primary
860 Data. *J Circadian Rhythms*. 2019 Jan 14;17:1.
- 861 87. Vernia F, Di Ruscio M, Ciccone A, Viscido A, Frieri G, Stefanelli G, et al. Sleep
862 disorders related to nutrition and digestive diseases: a neglected clinical condition. *Int J*
863 *Med Sci*. 2021 Jan 1;18(3):593–603.

- 864 88. Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, et al.
865 TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate
866 Underlie Central Effects of Monoamine Oxidase Inhibition. *Biol Psychiatry*. 2021 Jul
867 1;90(1):16–27.
- 868 89. Schwartz MD, Black SW, Fisher SP, Palmerston JB, Morairty SR, Hoener MC, et al.
869 Trace Amine-Associated Receptor 1 Regulates Wakefulness and EEG Spectral
870 Composition. *Neuropsychopharmacology*. 2017 May;42(6):1305–14.
- 871 90. Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace
872 amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric
873 diseases. *Expert Opin Ther Targets*. 2018 Jun 5;22(6):513–26.
- 874 91. Surendran P, Stewart ID, Au Yeung VPW, Pietzner M, Raffler J, Wörheide MA, et al.
875 Rare and common genetic determinants of metabolic individuality and their effects on
876 human health. *Nat Med*. 2022 Nov 10;28(11):2321–32.
- 877 92. Yap CX, Sidorenko J, Wu Y, Kemper KE, Yang J, Wray NR, et al. Dissection of genetic
878 variation and evidence for pleiotropy in male pattern baldness. *Nat Commun*. 2018 Dec
879 20;9(1):5407.
- 880 93. Pickrell JK, Berisa T, Liu JZ, Séguérel L, Tung JY, Hinds DA. Detection and
881 interpretation of shared genetic influences on 42 human traits. *Nat Genet*. 2016
882 Jul;48(7):709–17.
- 883 94. Pinilla L, Benítez ID, Gracia-Lavedan E, Torres G, Mínguez O, Vaca R, et al.
884 Metabolipidomic Analysis in Patients with Obstructive Sleep Apnea Discloses a
885 Circulating Metabotype of Non-Dipping Blood Pressure. *Antioxidants (Basel)*. 2023 Nov
886 27;12(12).
- 887 95. Cole LK, Vance JE, Vance DE. Phosphatidylcholine biosynthesis and lipoprotein
888 metabolism. *Biochim Biophys Acta*. 2012 May;1821(5):754–61.
- 889 96. Laird DA, Drexel H. Experimenting with Foods and Sleep I. Effects of Varying Types of
890 Food in Offsetting Sleep Disturb-Ances Caused by Hunger Pangs and Gastric Distress—
891 Children and Adults. *J Am Diet Assoc*. 1934 Jul;10(2):89–99.
- 892 97. Southwell PR, Evans CR, Hunt JN. Effect of a hot milk drink on movements during
893 sleep. *Br Med J*. 1972 May 20;2(5811):429–31.
- 894 98. Chua EC-P, Shui G, Cazenave-Gassiot A, Wenk MR, Gooley JJ. Changes in Plasma
895 Lipids during Exposure to Total Sleep Deprivation. *Sleep*. 2015 Nov 1;38(11):1683–91.
- 896 99. Yu Z, Zhai G, Singmann P, He Y, Xu T, Prehn C, et al. Human serum metabolic profiles
897 are age dependent. *Aging Cell*. 2012 Dec;11(6):960–7.

- 898 100. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-
899 Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol*. 2002 Nov
900 1;156(9):871–81.
- 901 101. Paynter NP, Balasubramanian R, Giulianini F, Wang DD, Tinker LF, Gopal S, et al.
902 Metabolic predictors of incident coronary heart disease in women. *Circulation*. 2018 Feb
903 20;137(8):841–53.

904 Figure Legends

905

906 Figure 1: Inclusion criteria for the current study from the HCHS/SOL study

907 Figure 2: Network of Metabolites and related pathways associated with EDS.

908

909

910 **Supplementary Materials**

911 **MESA Sleep Ancillary Study**

912 The Multi-Ethnic Study of Atherosclerosis (MESA) is a long-term study examining risk factors for heart disease in
913 four ethnic groups. The full study design has been previously published(100). The study began in 2000 and recruited
914 6,814 adults with no clinical cardiovascular disease aged 45-84 years old from 6 field centres across the United States
915 (Baltimore, MD; Chicago, IL; Los Angeles, CA; New York, NY; Saint Paul, MN; and Winston-Salem, NC). The fifth
916 follow up (Exam 5) took place between April 2010 and February 2013 and included 4,077 participants. Among this
917 group, 2,261 participants were included for the MESA Sleep Ancillary Study and asked to complete sleep
918 questionnaires in addition to Polysomnography and actigraphy data collection. Among this group, 2,240 participants
919 completed sleep questionnaires including ESS (11).

920

921 **Methods**

922 Metabolomic analysis in the MESA study was performed for the blood samples of 2,640 participants from exam 5, of
923 which 1,849 were part of the MESA Sleep Ancillary Study and completed the ESS questionnaire. Details regarding
924 metabolomic quantification using the Broad Institute and Beth Israel Metabolomics Platform has been described
925 elsewhere(26,101). Briefly, metabolite profiling utilized liquid chromatography tandem mass spectrometry (LC-MS)
926 with positive ion mode for water-soluble metabolites and lipids. Raw data was processed using TraceFinder 3.1 and
927 Progenesis Q1. For negative ionization mode, an Agilent 1290 LC system coupled with a Waters XBridge Amide
928 column and Agilent 6490 triple quadrupole mass spectrometer was employed. Isotope-labelled internal standards
929 ensured MS sensitivity. Pooled plasma samples were interspersed for quality control. Metabolite identities were
930 confirmed using authentic reference standards (26). In total, 4,380 metabolites were quantified from 1,868 exam 5
931 samples. Institutional Review Board approval was obtained at each study site and written informed consent was
932 obtained from all participants.

933

934 **Mendelian Randomization metabQTL data**

935 The Phase 1 Trans-Omics in Precision Medicine (TOPMed) metabQTL included metabolomics data from the
936 Childhood Asthma Management Program (CAMP) (N = 787 using the Broad platform), The Genetic Epidemiology
937 of Asthma in Costa Rica (CRA) study (N=1,758 using the Broad platform), Framingham Heart Study (FHS) (N =
938 3,021 using the Broad platform), MESA (n=998), Women's Health Initiative (WHI) (N = 1,024 using the Broad
939 platform and N= 545 using the Metabolon platform), Genetic Epidemiology of Chronic Obstructive Pulmonary
940 Disease (COPDGene) Study (N=6,302 using the Metabolon platform), and the Subpopulations and Intermediate
941 Outcome Measures in COPD Study (SPIROMICS) (N =1,924 using the platform) metabQTL summary statistics
942 included variants with MAF $\geq 0.5\%$.

943

944 **Sample Preparation**

945 Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. Several recovery
946 standards were added prior to the first step in the extraction process for QC purposes. To remove protein, dissociate
947 small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse
948 metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder
949 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two
950 separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for
951 analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative
952 ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to
953 remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.

954 **Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS)**

955


956 All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific
957 Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II)
958 source and Orbitrap mass analyser operated at 35,000 mass resolution. The sample extract was dried then reconstituted
959 in solvents compatible to each of the four methods. Each reconstitution solvent contained a series of standards at fixed
960 concentrations to ensure injection and chromatographic consistency. One aliquot was analysed using acidic positive
961 ion conditions, chromatographically optimized for more hydrophilic compounds. In this method, the extract was
962 gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm, 1.7 μ m) using water and methanol,
963 containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analysed
964 using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic
965 compounds. In this method, the extract was gradient eluted from the same afore mentioned C18 column using
966 methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at an overall higher organic content.
967 Another aliquot was analysed using basic negative ion optimized conditions using a separate dedicated C18 column.
968 The basic extracts were gradient eluted from the column using methanol and water, however with 6.5mM Ammonium
969 Bicarbonate at pH 8. The fourth aliquot was analysed via negative ionization following elution from a HILIC column
970 (Waters UPLC BEH Amide 2.1x150 mm, 1.7 μ m) using a gradient consisting of water and acetonitrile with 10mM
971 Ammonium Formate, pH 10.8. The MS analysis alternated between MS and data-dependent MSⁿ scans using dynamic
972 exclusion. The scan range varied slightly between methods but covered 70-1000 m/z. Raw data files are archived
973 and extracted as described below.

974 **Data Extraction and Compound Identification**

975 Raw data was extracted, peak-identified and QC processed using Metabolon's hardware and software. These systems
976 are built on a web-service platform utilizing Microsoft's .NET technologies, which run on high-performance
977 application servers and fibre-channel storage arrays in clusters to provide active failover and load-balancing.
978 Compounds were identified by comparison to library entries of purified standards or recurrent unknown entities.
979 Metabolon maintains a library based on authenticated standards that contains the retention time/index (RI), mass to
980 charge ratio (*m/z*), and chromatographic data (including MS/MS spectral data) on all molecules present in the library.
981 Furthermore, biochemical identifications are based on three criteria: retention index within a narrow RI window of
982 the proposed identification, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores
983 between the experimental data and authentic standards. The MS/MS scores are based on a comparison of the ions
984 present in the experimental spectrum to the ions present in the library spectrum. While there may be similarities
985 between these molecules based on one of these factors, the use of all three data points can be utilized to distinguish
986 and differentiate biochemicals. More than 3300 commercially available purified standard compounds have been
987 acquired and registered into LIMS for analysis on all platforms for determination of their analytical characteristics.
988 Additional mass spectral entries have been created for structurally unnamed biochemicals, which have been identified
989 by virtue of their recurrent nature (both chromatographic and mass spectral). These compounds have the potential to
990 be identified by future acquisition of a matching purified standard or by classical structural analysis.

991 **Metabolite Quantification and Data Normalization**

992 Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a data normalization step
993 was performed to correct variation resulting from instrument inter-day tuning differences. Essentially, each
994 compound was corrected in run-day blocks by registering the medians to equal one (1.00) and normalizing each data
995 point proportionately.

A**B**